Aytu BioPharma, Inc.

AYTU Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.

2.04 0.03 +1.49%
Market cap
$21.8M
P/E
0.0×
Fwd P/E
−9.2×
Dividend yield
—
F-score
3/9
Altman Z
−4.04
Beneish M
−3.48
Dividend safety
n/a
Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Jun '23 Jun '24 Jun '25 Jun '26
Piotroski F-Score
— 4 5 3 3 3 5 3 4 3
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(4.78) (7.57) (5.01) (0.34) (1.05) (4.76) (2.69) (3.18) (3.20) (4.04)
P/S ratio
33.70 0.94 2.05 2.32 1.28 0.21 0.05 0.24 0.21 0.46
Altman Z″-Score (non-manufacturers)
(23.90) (14.82) (11.08) 0.23 (2.65) (11.88) (7.58) (8.62) (8.14) (10.35)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.19
Beneish M-Score
(3.26) (0.96) (3.01) 0.15 (0.57) (5.46) (2.72) (3.06) (2.67) (3.48)
P/Operating CF
(33.21) (0.76) (4.31) (8.27) (13.37) (2.86) 0.57 (20.03) 4.88 6.01
P/B ratio
27.14 0.26 2.11 0.68 0.61 0.46 0.14 0.57 0.72 0.75
EV/Sales
33.43 (1.00) 1.20 1.10 0.90 0.20 (0.01) 0.17 0.07 0.30
EV/EBITDA
0.00 0.21 0.00 0.00 0.00 0.00 0.17 1.90 0.00 0.00
EV/FCF
(7.72) 0.22 (0.61) (0.76) (1.47) (0.45) 0.07 (0.97) (3.04) 5.32
Current Ratio
0.84 2.79 2.87 2.62 0.96 0.93 1.03 0.99 1.26 1.13
Net Debt/EBITDA
0.06 0.42 0.80 2.27 0.68 0.05 0.86 (0.85) 3.90 2.17
Debt/Equity
0.00 0.00 0.00 0.15 0.18 0.41 0.42 0.55 1.15 0.48
ROE
(319.60%) (116.94%) (264.55%) (26.68%) (50.12%) (119.62%) (40.76%) (47.24%) (58.10%) (52.55%)
ROA
(114.43%) (56.51%) (97.28%) (14.49%) (27.83%) (53.95%) (12.44%) (12.45%) (11.20%) (12.44%)
ROIC
(402.85%) (195.07%) 0.00% (21.59%) (32.72%) (159.24%) (32.58%) (4.35%) (49.77%) (19.99%)
Return on Tangible Assets
(34,416.36%) (161.86%) (264.34%) (29.03%) (6,227.46%) 7,310.42% (439.57%) (4,450.56%) (81.47%) (190.36%)
Average Days of Receivables
59.82 57.72 86.80 74.41 156.70 81.98 98.34 131.74 171.31 144.42
Earnings Yield
(418.31%) (295.13%) (233.33%) (20.88%) (70.50%) (552.17%) (309.28%) (100.35%) (87.16%) (63.72%)
Free Cash Flow Yield
(12.84%) (479.99%) (96.10%) (62.44%) (47.68%) (211.30%) (358.72%) (71.33%) (10.93%) 12.21%
Free Cash Flow per Share
(6,061.43) (4,974.24) (369.01) (151.43) (33.80) (19.61) (1.54) (0.31) (0.24) 0.26
Book value per Share
1,739.04 4,068.03 181.74 420.42 164.28 30.14 11.78 5.00 3.02 2.86
Free Cash Flow
(13.94) (16.41) (14.39) (34.22) (28.30) (28.82) (5.13) (1.72) (1.50) 3.25
EV/EBIT
0.00 0.19 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026